Copyright Reports & Markets. All rights reserved.

Global Adalimumab Biosimilar Market Insights and Forecast to 2026

Request for Sample of this report
Buy now

1 Study Coverage

  • 1.1 Adalimumab Biosimilar Product Introduction
  • 1.2 Market Segments
  • 1.3 Key Adalimumab Biosimilar Manufacturers Covered: Ranking by Revenue
  • 1.4 Market by Type
    • 1.4.1 Global Adalimumab Biosimilar Market Size Growth Rate by Type
    • 1.4.2 Tablet
    • 1.4.3 Oral Solution
  • 1.5 Market by Application
    • 1.5.1 Global Adalimumab Biosimilar Market Size Growth Rate by Application
    • 1.5.2 Hospital Pharmacy
    • 1.5.3 Retail Pharmacy
    • 1.5.4 Online Pharmacy
  • 1.6 Study Objectives
  • 1.7 Years Considered

2 Executive Summary

  • 2.1 Global Adalimumab Biosimilar Market Size, Estimates and Forecasts
    • 2.1.1 Global Adalimumab Biosimilar Revenue 2015-2026
    • 2.1.2 Global Adalimumab Biosimilar Sales 2015-2026
  • 2.2 Global Adalimumab Biosimilar, Market Size by Producing Regions: 2015 VS 2020 VS 2026
    • 2.2.1 Global Adalimumab Biosimilar Retrospective Market Scenario in Sales by Region: 2015-2020
    • 2.2.2 Global Adalimumab Biosimilar Retrospective Market Scenario in Revenue by Region: 2015-2020

3 Global Adalimumab Biosimilar Competitor Landscape by Players

  • 3.1 Adalimumab Biosimilar Sales by Manufacturers
    • 3.1.1 Adalimumab Biosimilar Sales by Manufacturers (2015-2020)
    • 3.1.2 Adalimumab Biosimilar Sales Market Share by Manufacturers (2015-2020)
  • 3.2 Adalimumab Biosimilar Revenue by Manufacturers
    • 3.2.1 Adalimumab Biosimilar Revenue by Manufacturers (2015-2020)
    • 3.2.2 Adalimumab Biosimilar Revenue Share by Manufacturers (2015-2020)
    • 3.2.3 Global Adalimumab Biosimilar Market Concentration Ratio (CR5 and HHI) (2015-2020)
    • 3.2.4 Global Top 10 and Top 5 Companies by Adalimumab Biosimilar Revenue in 2019
    • 3.2.5 Global Adalimumab Biosimilar Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
  • 3.3 Adalimumab Biosimilar Price by Manufacturers
  • 3.4 Adalimumab Biosimilar Manufacturing Base Distribution, Product Types
    • 3.4.1 Adalimumab Biosimilar Manufacturers Manufacturing Base Distribution, Headquarters
    • 3.4.2 Manufacturers Adalimumab Biosimilar Product Type
    • 3.4.3 Date of International Manufacturers Enter into Adalimumab Biosimilar Market
  • 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2015-2026)

  • 4.1 Global Adalimumab Biosimilar Market Size by Type (2015-2020)
    • 4.1.1 Global Adalimumab Biosimilar Sales by Type (2015-2020)
    • 4.1.2 Global Adalimumab Biosimilar Revenue by Type (2015-2020)
    • 4.1.3 Adalimumab Biosimilar Average Selling Price (ASP) by Type (2015-2026)
  • 4.2 Global Adalimumab Biosimilar Market Size Forecast by Type (2021-2026)
    • 4.2.1 Global Adalimumab Biosimilar Sales Forecast by Type (2021-2026)
    • 4.2.2 Global Adalimumab Biosimilar Revenue Forecast by Type (2021-2026)
    • 4.2.3 Adalimumab Biosimilar Average Selling Price (ASP) Forecast by Type (2021-2026)
  • 4.3 Global Adalimumab Biosimilar Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End

5 Market Size by Application (2015-2026)

  • 5.1 Global Adalimumab Biosimilar Market Size by Application (2015-2020)
    • 5.1.1 Global Adalimumab Biosimilar Sales by Application (2015-2020)
    • 5.1.2 Global Adalimumab Biosimilar Revenue by Application (2015-2020)
    • 5.1.3 Adalimumab Biosimilar Price by Application (2015-2020)
  • 5.2 Adalimumab Biosimilar Market Size Forecast by Application (2021-2026)
    • 5.2.1 Global Adalimumab Biosimilar Sales Forecast by Application (2021-2026)
    • 5.2.2 Global Adalimumab Biosimilar Revenue Forecast by Application (2021-2026)
    • 5.2.3 Global Adalimumab Biosimilar Price Forecast by Application (2021-2026)

6 North America

  • 6.1 North America Adalimumab Biosimilar by Country
    • 6.1.1 North America Adalimumab Biosimilar Sales by Country
    • 6.1.2 North America Adalimumab Biosimilar Revenue by Country
    • 6.1.3 U.S.
    • 6.1.4 Canada
  • 6.2 North America Adalimumab Biosimilar Market Facts & Figures by Type
  • 6.3 North America Adalimumab Biosimilar Market Facts & Figures by Application

7 Europe

  • 7.1 Europe Adalimumab Biosimilar by Country
    • 7.1.1 Europe Adalimumab Biosimilar Sales by Country
    • 7.1.2 Europe Adalimumab Biosimilar Revenue by Country
    • 7.1.3 Germany
    • 7.1.4 France
    • 7.1.5 U.K.
    • 7.1.6 Italy
    • 7.1.7 Russia
  • 7.2 Europe Adalimumab Biosimilar Market Facts & Figures by Type
  • 7.3 Europe Adalimumab Biosimilar Market Facts & Figures by Application

8 Asia Pacific

  • 8.1 Asia Pacific Adalimumab Biosimilar by Region
    • 8.1.1 Asia Pacific Adalimumab Biosimilar Sales by Region
    • 8.1.2 Asia Pacific Adalimumab Biosimilar Revenue by Region
    • 8.1.3 China
    • 8.1.4 Japan
    • 8.1.5 South Korea
    • 8.1.6 India
    • 8.1.7 Australia
    • 8.1.8 Taiwan
    • 8.1.9 Indonesia
    • 8.1.10 Thailand
    • 8.1.11 Malaysia
    • 8.1.12 Philippines
    • 8.1.13 Vietnam
  • 8.2 Asia Pacific Adalimumab Biosimilar Market Facts & Figures by Type
  • 8.3 Asia Pacific Adalimumab Biosimilar Market Facts & Figures by Application

9 Latin America

  • 9.1 Latin America Adalimumab Biosimilar by Country
    • 9.1.1 Latin America Adalimumab Biosimilar Sales by Country
    • 9.1.2 Latin America Adalimumab Biosimilar Revenue by Country
    • 9.1.3 Mexico
    • 9.1.4 Brazil
    • 9.1.5 Argentina
  • 9.2 Central & South America Adalimumab Biosimilar Market Facts & Figures by Type
  • 9.3 Central & South America Adalimumab Biosimilar Market Facts & Figures by Application

10 Middle East and Africa

  • 10.1 Middle East and Africa Adalimumab Biosimilar by Country
    • 10.1.1 Middle East and Africa Adalimumab Biosimilar Sales by Country
    • 10.1.2 Middle East and Africa Adalimumab Biosimilar Revenue by Country
    • 10.1.3 Turkey
    • 10.1.4 Saudi Arabia
    • 10.1.5 U.A.E
  • 10.2 Middle East and Africa Adalimumab Biosimilar Market Facts & Figures by Type
  • 10.3 Middle East and Africa Adalimumab Biosimilar Market Facts & Figures by Application

11 Company Profiles

  • 11.1 AET BioTech
    • 11.1.1 AET BioTech Corporation Information
    • 11.1.2 AET BioTech Description and Business Overview
    • 11.1.3 AET BioTech Sales, Revenue and Gross Margin (2015-2020)
    • 11.1.4 AET BioTech Adalimumab Biosimilar Products Offered
    • 11.1.5 AET BioTech Related Developments
  • 11.2 Amgen
    • 11.2.1 Amgen Corporation Information
    • 11.2.2 Amgen Description and Business Overview
    • 11.2.3 Amgen Sales, Revenue and Gross Margin (2015-2020)
    • 11.2.4 Amgen Adalimumab Biosimilar Products Offered
    • 11.2.5 Amgen Related Developments
  • 11.3 Boehringer Ingelheim
    • 11.3.1 Boehringer Ingelheim Corporation Information
    • 11.3.2 Boehringer Ingelheim Description and Business Overview
    • 11.3.3 Boehringer Ingelheim Sales, Revenue and Gross Margin (2015-2020)
    • 11.3.4 Boehringer Ingelheim Adalimumab Biosimilar Products Offered
    • 11.3.5 Boehringer Ingelheim Related Developments
  • 11.4 Coherus Biosciences
    • 11.4.1 Coherus Biosciences Corporation Information
    • 11.4.2 Coherus Biosciences Description and Business Overview
    • 11.4.3 Coherus Biosciences Sales, Revenue and Gross Margin (2015-2020)
    • 11.4.4 Coherus Biosciences Adalimumab Biosimilar Products Offered
    • 11.4.5 Coherus Biosciences Related Developments
  • 11.5 Fujifilm Kyowa Kirin Biologics
    • 11.5.1 Fujifilm Kyowa Kirin Biologics Corporation Information
    • 11.5.2 Fujifilm Kyowa Kirin Biologics Description and Business Overview
    • 11.5.3 Fujifilm Kyowa Kirin Biologics Sales, Revenue and Gross Margin (2015-2020)
    • 11.5.4 Fujifilm Kyowa Kirin Biologics Adalimumab Biosimilar Products Offered
    • 11.5.5 Fujifilm Kyowa Kirin Biologics Related Developments
  • 11.6 LG Life Sciences/Mochida Pharmaceutical
    • 11.6.1 LG Life Sciences/Mochida Pharmaceutical Corporation Information
    • 11.6.2 LG Life Sciences/Mochida Pharmaceutical Description and Business Overview
    • 11.6.3 LG Life Sciences/Mochida Pharmaceutical Sales, Revenue and Gross Margin (2015-2020)
    • 11.6.4 LG Life Sciences/Mochida Pharmaceutical Adalimumab Biosimilar Products Offered
    • 11.6.5 LG Life Sciences/Mochida Pharmaceutical Related Developments
  • 11.7 Momenta Pharmaceuticals
    • 11.7.1 Momenta Pharmaceuticals Corporation Information
    • 11.7.2 Momenta Pharmaceuticals Description and Business Overview
    • 11.7.3 Momenta Pharmaceuticals Sales, Revenue and Gross Margin (2015-2020)
    • 11.7.4 Momenta Pharmaceuticals Adalimumab Biosimilar Products Offered
    • 11.7.5 Momenta Pharmaceuticals Related Developments
  • 11.8 Oncobiologics
    • 11.8.1 Oncobiologics Corporation Information
    • 11.8.2 Oncobiologics Description and Business Overview
    • 11.8.3 Oncobiologics Sales, Revenue and Gross Margin (2015-2020)
    • 11.8.4 Oncobiologics Adalimumab Biosimilar Products Offered
    • 11.8.5 Oncobiologics Related Developments
  • 11.9 Pfizer
    • 11.9.1 Pfizer Corporation Information
    • 11.9.2 Pfizer Description and Business Overview
    • 11.9.3 Pfizer Sales, Revenue and Gross Margin (2015-2020)
    • 11.9.4 Pfizer Adalimumab Biosimilar Products Offered
    • 11.9.5 Pfizer Related Developments
  • 11.10 Samsung Bioepsis
    • 11.10.1 Samsung Bioepsis Corporation Information
    • 11.10.2 Samsung Bioepsis Description and Business Overview
    • 11.10.3 Samsung Bioepsis Sales, Revenue and Gross Margin (2015-2020)
    • 11.10.4 Samsung Bioepsis Adalimumab Biosimilar Products Offered
    • 11.10.5 Samsung Bioepsis Related Developments
  • 11.1 AET BioTech
    • 11.1.1 AET BioTech Corporation Information
    • 11.1.2 AET BioTech Description and Business Overview
    • 11.1.3 AET BioTech Sales, Revenue and Gross Margin (2015-2020)
    • 11.1.4 AET BioTech Adalimumab Biosimilar Products Offered
    • 11.1.5 AET BioTech Related Developments
  • 11.12 Zydus Cadila
    • 11.12.1 Zydus Cadila Corporation Information
    • 11.12.2 Zydus Cadila Description and Business Overview
    • 11.12.3 Zydus Cadila Sales, Revenue and Gross Margin (2015-2020)
    • 11.12.4 Zydus Cadila Products Offered
    • 11.12.5 Zydus Cadila Related Developments

12 Future Forecast by Regions (Countries) (2021-2026)

  • 12.1 Adalimumab Biosimilar Market Estimates and Projections by Region
    • 12.1.1 Global Adalimumab Biosimilar Sales Forecast by Regions 2021-2026
    • 12.1.2 Global Adalimumab Biosimilar Revenue Forecast by Regions 2021-2026
  • 12.2 North America Adalimumab Biosimilar Market Size Forecast (2021-2026)
    • 12.2.1 North America: Adalimumab Biosimilar Sales Forecast (2021-2026)
    • 12.2.2 North America: Adalimumab Biosimilar Revenue Forecast (2021-2026)
    • 12.2.3 North America: Adalimumab Biosimilar Market Size Forecast by Country (2021-2026)
  • 12.3 Europe Adalimumab Biosimilar Market Size Forecast (2021-2026)
    • 12.3.1 Europe: Adalimumab Biosimilar Sales Forecast (2021-2026)
    • 12.3.2 Europe: Adalimumab Biosimilar Revenue Forecast (2021-2026)
    • 12.3.3 Europe: Adalimumab Biosimilar Market Size Forecast by Country (2021-2026)
  • 12.4 Asia Pacific Adalimumab Biosimilar Market Size Forecast (2021-2026)
    • 12.4.1 Asia Pacific: Adalimumab Biosimilar Sales Forecast (2021-2026)
    • 12.4.2 Asia Pacific: Adalimumab Biosimilar Revenue Forecast (2021-2026)
    • 12.4.3 Asia Pacific: Adalimumab Biosimilar Market Size Forecast by Region (2021-2026)
  • 12.5 Latin America Adalimumab Biosimilar Market Size Forecast (2021-2026)
    • 12.5.1 Latin America: Adalimumab Biosimilar Sales Forecast (2021-2026)
    • 12.5.2 Latin America: Adalimumab Biosimilar Revenue Forecast (2021-2026)
    • 12.5.3 Latin America: Adalimumab Biosimilar Market Size Forecast by Country (2021-2026)
  • 12.6 Middle East and Africa Adalimumab Biosimilar Market Size Forecast (2021-2026)
    • 12.6.1 Middle East and Africa: Adalimumab Biosimilar Sales Forecast (2021-2026)
    • 12.6.2 Middle East and Africa: Adalimumab Biosimilar Revenue Forecast (2021-2026)
    • 12.6.3 Middle East and Africa: Adalimumab Biosimilar Market Size Forecast by Country (2021-2026)

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

  • 13.1 Market Opportunities and Drivers
  • 13.2 Market Challenges
  • 13.3 Market Risks/Restraints
  • 13.4 Porter's Five Forces Analysis
  • 13.5 Primary Interviews with Key Adalimumab Biosimilar Players (Opinion Leaders)

14 Value Chain and Sales Channels Analysis

  • 14.1 Value Chain Analysis
  • 14.2 Adalimumab Biosimilar Customers
  • 14.3 Sales Channels Analysis
    • 14.3.1 Sales Channels
    • 14.3.2 Distributors

15 Research Findings and Conclusion

    16 Appendix

    • 16.1 Research Methodology
      • 16.1.1 Methodology/Research Approach
      • 16.1.2 Data Source
    • 16.2 Author Details

    Adalimumab Biosimilar market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Adalimumab Biosimilar market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.

    Segment by Type, the Adalimumab Biosimilar market is segmented into
    Tablet
    Oral Solution

    Segment by Application, the Adalimumab Biosimilar market is segmented into
    Hospital Pharmacy
    Retail Pharmacy
    Online Pharmacy

    Regional and Country-level Analysis
    The Adalimumab Biosimilar market is analysed and market size information is provided by regions (countries).
    The key regions covered in the Adalimumab Biosimilar market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
    The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
    Competitive Landscape and Adalimumab Biosimilar Market Share Analysis
    Adalimumab Biosimilar market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Adalimumab Biosimilar business, the date to enter into the Adalimumab Biosimilar market, Adalimumab Biosimilar product introduction, recent developments, etc.

    The major vendors covered:
    AET BioTech
    Amgen
    Boehringer Ingelheim
    Coherus Biosciences
    Fujifilm Kyowa Kirin Biologics
    LG Life Sciences/Mochida Pharmaceutical
    Momenta Pharmaceuticals
    Oncobiologics
    Pfizer
    Samsung Bioepsis
    Sandoz
    Zydus Cadila

    Buy now